Michael Barbella, Managing Editor11.07.22
NuVasive Inc. has commercially launched the NuVasive Tube System (NTS) and Excavation Micro, a new minimally invasive surgery (MIS) system that provides comprehensive solutions for both TLIF and decompression. These additions expand the company's access and instrumentation technology offerings within the NuVasive P360 portfolio.
"There's a clear opportunity to transform surgery within the $1.7 billion-dollar thoracolumbar posterior procedure segment and we're seizing it with P360," Chief Technology Officer Ryan Donahoe said. "Our P360 portfolio is now complemented by the launch of our NTS and Excavation Micro solutions that are specifically designed to increase workflow speed while delivering improved safety and reproducibility."
Engineered to elevate the surgical workflow through efficient, controlled positioning, and optimized access, NTS and Excavation Micro are made a complete procedural solution with Advanced Materials Science and expandable interbody implants, biologics, Reline fixation system, and enabling technologies within the Pulse platform.
"The tube systems on the market haven't really changed much in the past 20 years. Now with NTS, I'm able to tackle two procedures with the same system through the incredible access design—which further extends NuVasive as the market leader in access innovation," said Dr. David Yam, neurosurgeon in Portland, Oregon at Legacy Medical Group. "Even with more complex surgeries, I'm able complete the case through a tube, rather than reverting to an open procedure."
NuVasive Inc.'s less-invasive, procedurally integrated surgical solutions are designed to deliver reproducible and clinically proven outcomes. Its procedural portfolio includes surgical access instruments, spinal implants, fixation systems, biologics, software for surgical planning, navigation and imaging solutions, magnetically adjustable implant systems for spine and orthopedics, and intraoperative neuromonitoring technology and service offerings. With more than $1 billion in net sales, NuVasive operates in more than 50 countries serving surgeons, hospitals, and patients.
"There's a clear opportunity to transform surgery within the $1.7 billion-dollar thoracolumbar posterior procedure segment and we're seizing it with P360," Chief Technology Officer Ryan Donahoe said. "Our P360 portfolio is now complemented by the launch of our NTS and Excavation Micro solutions that are specifically designed to increase workflow speed while delivering improved safety and reproducibility."
Engineered to elevate the surgical workflow through efficient, controlled positioning, and optimized access, NTS and Excavation Micro are made a complete procedural solution with Advanced Materials Science and expandable interbody implants, biologics, Reline fixation system, and enabling technologies within the Pulse platform.
"The tube systems on the market haven't really changed much in the past 20 years. Now with NTS, I'm able to tackle two procedures with the same system through the incredible access design—which further extends NuVasive as the market leader in access innovation," said Dr. David Yam, neurosurgeon in Portland, Oregon at Legacy Medical Group. "Even with more complex surgeries, I'm able complete the case through a tube, rather than reverting to an open procedure."
NuVasive Inc.'s less-invasive, procedurally integrated surgical solutions are designed to deliver reproducible and clinically proven outcomes. Its procedural portfolio includes surgical access instruments, spinal implants, fixation systems, biologics, software for surgical planning, navigation and imaging solutions, magnetically adjustable implant systems for spine and orthopedics, and intraoperative neuromonitoring technology and service offerings. With more than $1 billion in net sales, NuVasive operates in more than 50 countries serving surgeons, hospitals, and patients.